10.0 References

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376.
2. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (for the European Organization for Research and Treatment of Cancer Study Group on Quality of Life) (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376.
3. Adamson S (1985) Through the Gateway of the Heart: Accounts of Experiences with MDMA and Other Empathogenic Substances. San Francisco: Four Trees Publications.
4. Aghajanian GK, Lieberman JA (2001) Response. Neuropsychopharmacol 24:335-336.
5. Alting Von Geusau N, Stalenhoef, P, Huizinga M, Snel J, Ridderinkhof KR (2004) Impaired executive function in male MDMA (Ecstasy) users. Psychopharmacology (Berl), Published online March 18, 2004. DOI: 10.1007/s00213-004-1832-8.
6. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington DC: American Psychiatric Association Press.
7. Anonymous (1999) Series of letters on MDMA and cancer. MAPS Bulletin 9(1):56-59.
8. Back-Madruga C, Boone KB, Chang L, Grob CS, Lee A, Nations H, Poland RE (2003) Neuropsychological effects of 3,4- methylenedioxymethamphetamine (MDMA or Ecstasy) in recreational users. Clin Neuropsychol 17:446-459.
9. Baggott M (2002) Preventing problems in ecstasy users; Reduce use to reduce harm. J Psychoactive Drugs 34:145-162.
10. Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J (2000) Chemical analysis of ecstasy pills JAMA 284:2190.
11. Baggott M, Mendelson J (2001) Does MDMA cause brain damage? In Holland J (Ed), Ecstasy, A Complete Guide. Rochester VT: Inner Tradition, 110-145.
12. Beck AT, Steer RA. (1988) Manual for the Beck Hopelessness Scale. New York: Psychological Corporation.
13. Beck A, Weissman A, Lester D, Trexler L (1974) The measurement of pessimism: the Beck Hopelessness Scale. J Consult Clin Psychol 42:861-865.
14. Bhattachary S, Powell JH (2001) Recreational use of 3,4- methylenedioxymethamphetamine (MDMA) or 'ecstasy': Evidence for cognitive impairment. Psychological Med 31:647-658.
15. Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51:1532-1537. Bond AJ, Verheyden SL, Wingrove J, Curran HV (2004) Angry cognitive bias, trait aggression and impulsivity in substance users. Psychopharmacol (Berl) 171:331-339.
16. Bonny HL, Savary LM (1990) Music and Your Mind. Tarrytown NY: Station Hill.
17. Boone KB, Chang L, Grob CS, Poland RE (unpublished, in preparation) Neuropsychological effects of 3,4- methylenedioxymethamphetamine (MDMA or Ecstasy) Unpublished data, presented on p. 24-25 in the Investigator's Brochure.
18. Bouso JC (2001) Using MDMA in the treatment of posttraumatic stress disorder. In Holland J (Ed), Ecstasy, A Complete Guide. Rochester VT: Inner Traditions, 248-260.
19. Bowyer JF, Young JF, Slikker W, Itzak Y, Mayorga AJ, Newport GD, Ali SF, Frederick DL, Paule MG (2003) Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicol 24:379-390.
20. Brady M, Peterman A, Fitchett G, Mo M, Cella D (1999) A case for including spirituality in quality of life measurement in oncology. Psycho-Oncology 8:417-428.
21. Breitbart W, Rosenfeld B, Pessin H, Pessin H, Kaim M, Funesti-Esch J, Galietta M, Nelson CJ, Brescia R (2000) Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 284:2907-2911.
22. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV (2003) 3,4-Methylenedioxymethamphetamine (Ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 21:3228-3235.
23. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of "Ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 44:375-384.
24. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4- methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20:455-466.
25. Carvalho M, Carvalho F, Bastos ML (2001) Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4- methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes. Arch Toxicol 74:789-793.
26. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002a) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547-561.
27. Cella D, Nowinski CJ (2002b) Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 83(12 Suppl 2):S10-S17.
28. Chang L, Ernst T, Grob CS, Poland RE (1999) Cerebral (1)H MRS alterations in recreational 3, 4- methylenedioxymethamphetamine (MDMA, 'ecstasy') users. J Magn Reson Imaging 10: 521-526.
29. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE (2000) Effect of ecstasy [3,4- methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res 98:15-28.
30. Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA (2002) The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97:1531-1536.
31. Cole JC, Sumnall HR (2003) Altered states: the clinical effects of Ecstasy. Pharmacol Ther 98:35-58.
32. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241:338-345.
33. Cowan RL, Lyoo IK, Sung SM, Ahn KH, Kim MJ, Hwang J, Haga E, Vimal RL, Lukas SE, Renshaw PF (2003) Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. Drug Alcohol Depend 72:225-235.
34. Crisp T, Stafinsky JL, Boja JW, Schechter MD (1989) The antinociceptive effects of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. Pharmacol Biochem Behav 34:497-501.
35. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH (2001) The relative contribution of ecstasy and cannabis to cognitive impairment. Psychopharmacol (Berl) 153:373-379.
36. Curran HV, Verheyden SL (2003) Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function. Psychopharmacol (Berl) 169:91-103.
37. Dafters RI, Hoshi R, Talbot AC (2004) Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users. Psychopharmacol (Berl) 173:405-410.
38. Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E (2001) Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use. Hum Psychopharmacol 16:627-633.
39. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E (2004) Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross- sectional/longitudinal investigation. Psychopharmacol (Berl) 173:398-404.
40. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J, Cami J (2000a) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49: 104-109.
41. de la Torre R, Farre M, Roset PN, Hernandez Lopez C, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, Cami J (2000b) Pharmacology of MDMA in humans. Ann N Y Acad Sci 914:225-237.
42. De Win MM, Reneman L, Reitsma JB, Den Heeten GJ, Booij J, Van Den Brink W (2004) Mood disorders and serotonin transporter density in ecstasy users-the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) 173:376-382.
43. Derogatis LR (1994) SCL-90-R: Administration, Scoring and Procedures Manual. National Computer Systems, Inc., Minneapolis.
44. Doblin R (2004) Personal communication to J Halpern and L Jerome, July 12, 2004 via electronic mail.
45. Doblin R (2002) A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA. J Psychoactive Drugs 34:185-194.
46. d'Otalora, M (2004) MDMA and LSD Therapy in the Treatment of Post Traumatic Stress Disorder in a Case of Sexual Abuse. http://www.maps.org/research/mdma/moaccount.html
47. Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18:335-340.
48. Farre M, De La Torre R, O Mathuna B, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, Cami J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173:364-375.
49. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0, 4/97 Revision). New York; Biometrics Research Department, New York State Psychiatric Institute.
50. Folstein M, Folstein S, McHugh P (1975) Mini-mental state": a practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
51. Forsling M, Fallon JA, Kicman AT, Hutt AJ, Cowan DA, Henry JA (2001) Arginine vasopressin release in response to the administration of 3,4- methylenedioxymethamphetamine ("ecstasy"): Is metabolism a contributory factor? J Pharmacy Pharmacol 53:1357-1363.
52. Fox HC, McLean A, Turner JJ, Parrott AC, Rogers R, Sahakian BJ (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology (Berl) 162:203-214.
53. Friedman HL (1983) The Self-Expansiveness Level Form: A conceptualization and measurement of a transpersonal construct. J Transpersonal Psychology 15:37-50.
54. Gasser P (1994) Psycholytic Therapy with MDMA and LSD in Switzerland. MAPS Newsletter 5(3):3-7.
55. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F (2000) Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 47:127-136.
56. Gerra G, Zaimovic A, Ampollini R, Giusti F, Delsignore R, Raggi MA, Laviola G, Macchia T, Brambilla F (2001) Experimentally induced aggressive behavior in subjects with 3,4-methylenedioxy- methamphetamine ("Ecstasy") use history: psychobiological correlates. J Subst Abuse 13:471-491.
57. Gijsman HJ, Verkes RJ, van Gerven JM, Cohen AF (1999) MDMA study (Letter to the Editor). Neuropsychopharmacol 21:597.
58. Gore SM (1999) Fatal uncertainty: death-rate from use of ecstasy or heroin. Lancet 354:1265-1266.
59. Gouzoulis-Mayfrank, E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 68:719-725.
60. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hansen G, Daumann J (2003) Memory impairments suggest hippocampal dysfunction in abstinent Ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 27:819-827.
61. Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4- methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacol (Berl) 119:247-260.
62. Greer G, Tolbert RA (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18:319-327.
63. Greer GR, Tolbert R (1998) A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 30:371-379.
64. Grinspoon L, Bakalar JB (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40:393-404.
65. Grob CS, Poland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73:103-107.
66. Grob CS, Poland RE, Boone KB (unpublished) Psychological, physiological and neuroendocrine effects of 3,4- methylenedioxymethamphetamine (MDMA, "Ecstasy") in healthy humans. Data presented in Investigators' Brochure.
67. Grof S (1980) LSD Psychotherapy. Alameda CA: Hunter House.
68. Grof S (2000) The Psychology of the Future. Albany: SUNY Press.
69. Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JH, Yurgelun- Todd D (2004) Residual neuropsychological effects of illicit 3,4- methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75: 135-147. DOI: 10.1016/k/drugalcdep.2004.02.008.
70. Hamilton, M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
71. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-61.
72. Hamilton M (1967) Development of a rating scale; for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
73. Hanson KL and Luciana M (2004) Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 34:229-246.
74. Harris DS, Baggott M, Mendelson J, Mendelson JE, Jones RT (2002) Subjective and hormonal effects of 3,4- methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacol (Berl) 162:396-405.
75. Hatzidimitriou G, McCann UD, Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19:5096-5107.
76. Hegadoren KM, Baker GB, Bourin M (1999) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23:539-553.
77. Henry JA, Rella JG (2001) Medical risks associated with MDMA use. In Holland J (Ed). Ecstasy, A Complete Guide. Rochester VT: Inner Traditions, 71-86.
78. Hernandez-Lopez C, Farre M, Roset PN, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R (2002) 3,4- Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300: 236-244.
79. Holland J (Ed) (2001) Ecstasy, a Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester VT: Inner Traditions.
80. Karnofsky D, Burchenal J (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C (Ed) Evaluation of chemotherapeutic agents. New York: Columbia University Press, 191-205.
81. Kish SJ (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 71:845-855.
82. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS (2000) Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology 55:294-296
83. Lamers CTJ, Ramaekers JG, Muntjewerff ND, Sikkema KL, Samyn N, Read NL, Brookhuis KA, Riedel WJ (2003) Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol 17:379-387.
84. Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J (2000) Cardiovascular effects of 3,4- methylenedioxymethamphetamine. A double-blind, placebo- controlled trial. Ann Intern Med 133:969-973.
85. Lew, R, Sabol KE, Chou C, Vosmer GL, Richards J, Seiden LS (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. J Pharmacol Exp Ther 276:855-865.
86. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68:195-207.
87. Lieberman JA, Aghajanian GK (1999) Caveat emptor: Researcher beware. Neuropsychopharmacol 21:471-473.
88. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000a) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacol 22:513-521.
89. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000b) Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacol 23:396-404.
90. Liechti ME, Gamma A, Vollenweider FX (2001a) Gender differences in the subjective effects of MDMA. Psychopharmacol 154:161-168.
91. Liechti ME, Geyer MA, Hell D, Vollenweider FX (2001b) Effects of MDMA (Ecstasy) on pre-pulse inhibition and habituation of startle in humans after pretreatment with citalopam, haloperidol, or ketanserin. Neuropsychopharmacol 24:240-252.
92. Liechti ME, Vollenweider FX (2000a) Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10:289-295.
93. Liechti ME, Vollenweider FX (2000b) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14:269-274.
94. Ludewig S, Ludewig K, Hasler F, Vollenweider FX (2003) No lasting effects of moderate doses of MDMA (Ecstasy) on memory performance and mood states in health humans. Biol Psychiatry 53 (Suppl); 205S. Data presented at the 58th Annual Conference of the Society for Biological Psychiatry, San Francisco, CA.
95. MacPherson RD (2002) New directions in pain management. Drugs of Today 38:135-145.
96. Mahmood I, Balian JD (1996) Interspecies scaling; A comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 59:579-585.
97. Martin DC, Rubin FH, (1997) Anatomy and physiology of the aging brain. In Nussbaum, PD (Ed). The Handbook of Neuropsychology and Aging. New York: Plenum Press. (pp. 32- 43).
98. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136-145.
99. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352:1433-1437.
100. McCann U, Mertl M, Eligulashvili V, Ricaurte GA (1999) Cognitive performance in 3,4-methylenedioxymethamphetamine (MDMA) users: A controlled study. Psychopharmacol 143:417-425.
101. McCann UD, Ricaurte G (2001) Caveat emptor: Editors beware. Neuropsychopharmacol 24:333-334.
102. McCardle, K, Luebbers, S, Carter JD, Croft RJ, Stough C (2004) Chronic MDMA (Ecstasy) use, cognition and mood. Psychopharmacology (Berl), Published online April 18, 2004. DOI: 10.1007/s00213-004-1791-0.
103. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH (1999) Congenital anomalies after prenatal ecstasy exposure. Lancet 354:1441-1442.
104. McClain CS, Rosenfeld B, Breitbart W (2003) Effect of spiritual well- being on end-of-life despair in terminally ill cancer patients. Lancet 361:1603-1607.
105. Metzner R, Adamson S (2001) Using MDMA in Healing, Psychotherapy and Spiritual Practice. In Holland J (Ed), Ecstasy, A Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester, VT: Inner Traditions: 182-207. Originally published in ReVision 10(4) (1988) The nature of the MDMA experience and its role in healing, psychotherapy and spiritual practice.
106. Miller DB, O'Callaghan JP (1996) Neurotoxicity of d-amphetamine in the C57BL/6J and CD-1 mouse. Interactions with stress and the adrenal system. Ann N Y Acad Sci 801:148-167.
107. Mithoefer M (2004) MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder; a fourth update on the approval process and first report on study progress. MAPS Bulletin 14(1): 3-4.
108. Mithoefer M, Wagner M (2001) a human phase II study - Safety and efficacy of 3,4-methylenedioxymethamphetamine (MDMA)- assisted psychotherapy in the treatment of chronic posttraumatic stress disorder (PTSD). Protocol submitted to the Food and Drug Administration, October 2001. On-line copy available at http://www.maps.org/research/mdma/protocol/mdmaptsdvol1- sm.pdf
109. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA (1990) Neurotoxicity of MDMA and related compounds: Anatomic studies. Ann N Y Acad Sci 600:649-661; discussion 661-664.
110. Montgomery S, Bech P (2000) ECNP consensus meeting, March 5-6, 1999, Nice. Post traumatic stress disorder: Guidelines for investigating efficacy of pharmacological intervention. ECNP and ECST. European Neuropsychopharmacol 10:297-303.
111. Morgan MJ (1999) Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacol (Berl) 141:30-36.
112. Naranjo C (2001) Experience with the interpersonal psychedelics. In Holland J (Ed), Ecstasy, a Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester, VT: Inner Traditions, 208-221.
113. Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305-313.
114. Nichols DE, Oberlender R (1990) Structure-activity relationships of MDMA and related compounds: A new class of psychoactive agents? In Peroutka SJ (Ed), Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Holland: Kluwer.
115. Obergriesser T, Ende G, Braus DF, Henn FA (2001) Hippocampal [1H]- MRSI in ecstasy users. European Archives of Psychiatry and Clin Neurosci 251:114-116.
116. Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, Schiemann T (1999) Ecstasy--long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 175:186-188.
117. O'Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
118. Office of Applied Studies, Substance Abuse and Mental Health Services Administration. (2003). Results from the 2002 National Survey on Drug Use and Health: Detailed tables available online http://www.oas.samhsa.gov/nhsda/2k2nsduh/html/Sect1peTabs 1to110A.htm#tab1.1a.
119. Ohnhaus EE, Adler R (1975) Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. Pain 1:379-384.
120. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Segura J, de la Torre R (1999) Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci 65:L309-L316.
121. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Hernandez Lopez C, Ortuno J, Segura J, Cami J, de la Torre R (2000) Immunomodulating activity of MDMA. Ann N Y Acad Sci 914:215-224.
122. Pacifici R, Zuccaro P, Lopez CH, Pichini S, Di Carlo S, Farre M, Roset PN, Ortuno J, Segura J, Torre RL (2001) Acute effects of 3,4- methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 296:207-215.
123. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Palmi I, Ortuno J, Menoyo E, Segura J, de la Torre R (2002) Cell- mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann N Y Acad Sci 965:421-433.
124. Pacifici R, Pichini S, Zuccaro P, Farre M, Segura M, Ortuno J, Di Carlo S, Bacosi A, Roset P, Segura J, De La Torre R (2004) Paroxetine inhibits acute effects of MDMA on the immune system in humans. J Pharmacol Exp Ther 309:285-292.
125. Peterman AH, Fitchett G, Brady MJ, Hernandez L, Cella D (2002) Measuring spiritual well-being in individuals with cancer: the functional assessment of chronic illness therapy--Spiritual Well- being Scale (FACIT-Sp). Ann Behav Med 24:49-58.
126. Pichini S, Navarro M, Farre M, Ortuno J, Roset PN, Pacifici R, Zuccaro P, Segura J, de la Torre R (2002) On-site testing of 3,4- methylenedioxymethamphetamine (ecstasy) in saliva with Drugwipe and Drugread: a controlled study in recreational users. Clin Chem 48:174-176.
127. Pichini S, Navarro M, Pacifici R, Zuccaro P, Ortuno J, Farre M, Roset PN, Segura J, de la Torre R (2003) Usefulness of sweat testing for the detection of MDMA after a single-dose administration. J Anal Toxicol 27:294-303.
128. Pizarro N, Ortuno J, Farre M, Hernandez-Lopez C, Pujadas M, Llebaria A, Joglar J, Roset PN, Mas M, Segura J, Cami J, de la Torre R (2002) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157-165.
129. Pizarro N, Llebaria A, Cano S, Joglar J, Farre M, Segura J, de la Torre R (2003) Stereochemical analysis of 3,4- methylenedioxymethamphetamine and its main metabolites by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 17:330-336.
130. Portenoy R, Thaler H, Kornblith A, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L (1994) The Memorial Symptom Assessment Scale: an instrument for evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326-1336.
131. Potter VT, Wiseman CE, Dunn SM, Boyle FM (2003) Patient barriers to optimal cancer pain control. Psycho-Oncology 12:153-160.
132. Randall-David E, Wright J, Porterfield DS, Lesser G (2003) Barriers to cancer pain management: home-health and hospice nurses and patients. Supportive Care Cancer 11:660-665.
133. Reneman L, Habraken JB, Majoie CB, Booij J, den Heeten GJ (2000) MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. AJNR Am J Neuroradiol 21:1001-1007.
134. Reneman L, Booij K, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W (2001a) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358:1864-1869.
135. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J (2001b) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4- methylenedioxymethamphetamine (MDMA or "Ecstasy"): preliminary findings. Arch Gen Psychiatry 58:901-906.
136. Reneman, L, Majoie, CBLM, Schmand, B, van den Brink, W and den Heeten, GJ (2001c). Pre-frontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: Preliminary report. Biological Psychiatry, 50: 550-554.
137. Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, de Wolff F, Booij J (2002a). The acute and chronic effects of MDMA ("Ecstasy") on cortical 5HT2A receptors in rat and human brain. Neuropsychopharmacol 26:387-396.
138. Reneman L, Majoie CB, Flick H, den Heeten GJ (2002b) Reduced N- acetylaspartate levels in the frontal cortex of 3,4- methylenedioxymethamphetamine (Ecstasy) users: preliminary results. AJNR Am J Neuroradiol 23:231-237.
139. Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma JB, Boudewijn Gunning W, den Heeten, GJ, van den Brink W (2002c) Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: A [123I]-Beta-CIT SPECT study - preliminary report. Psychopharmacol (Berl) 159:335-340.
140. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science 297:2260-2263.
141. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2003) Retraction. Science 301:1479.
142. Ricaurte GA (2004) Grant Progress Report. Obtained via Freedom of Information Act (FOIA) Request on January 16, 2004. Link: http://www.maps.org/mdma/retraction/foia012804/progress1.h ml.
143. Rodgers J (2000) Cognitive performance amongst recreational users of "ecstasy." Psychopharmacol (Berl) 151:19-24.
144. Rosenfeld B, Breitbart W, Stein K, Funesti-Esch J, Kaim M, Krivo S, Galietta M (1999). Measuring desire for death among patients with HIV/AIDS: the Schedule of Attitudes Toward Hastened Death. Am J Psychiatry 156:94-100.
145. Ruse J, Jerome L, Mithoefer M, Doblin R (2002) MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder (PTSD): A Treatment Manual Draft. MAPS.
146. Ruse J, Jerome L, Halpern JH, Doblin R (2004) MDMA-Assisted Psychotherapy for the Treatment of Anxiety Associated with a Diagnosis of Advanced Stage Cancer: A Treatment Manual Draft. MAPS.
147. Sabol KE, Lew R, Richards JB, Vosmer GL, Seiden LS (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. J Pharmacol Exp Ther 276:846-854.
148. Seiden LS, Kleven MS (1989) Methamphetamine and related drugs: toxicity and resulting behavioral changes in response to pharmacological probes. NIDA Res Monogr 94:146-160.
149. Seiden LS, Sabol KE (1996) Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr 163:251-276.
150. Segura M, Ortuno J, Farre M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, de La Torre R (2001) Links 3,4- Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14:1203-1208.
151. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175:63-69.
152. Shulgin AT (1990) History of MDMA. In SJ Peroutka (Ed.) Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Boston: Kluwer Academic Publishers.
153. Shulgin AT, Nichols DE (1978) Characterization of three new psychotomimetics. In: Stillman RC, Willette RE (eds.) The Pharmacology of Hallucinogens. New York: Pergamon.
154. Shvartzman P, Friger M, Shani A, Barak F, Yoram C, Singer Y (2003) Pain control in ambulatory cancer patients--can we do better? J Pain Symptom Management 26:716-722.
155. Simon NG, Mattick RP (2002) The impact of regular Ecstasy use on memory function. Addiction 97:1523-1529.
156. Spielberger CS, Gorsuch RL, Lushene RE (1970) Manual for the State Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.
157. Stevens S (1997) Speaking the silence: MDMA in a couple dealing with cancer. MAPS Bulletin 7(4):6-10.
158. Stevens S (1999) MDMA in a couple struggling with cancer: Two years later. MAPS Bulletin 9(3):15-17.
159. Stevens S (2000) MDMA and a couple struggling with cancer: Sue's final letter. MAPS Bulletin 9(4):31-34.
160. Stolaroff M (1997) The Secret Chief: Conversations with a pioneer of the underground therapy movement. Sarasota FL: Multidisciplinary Association for Psychedelic Studies.
161. Tancer, ME (2003) Personal communication to L Jerome, January 17, 2003.
162. Tancer ME, Johnson CE (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65:97-101.
163. Tancer M, Johanson C-E (2003) Reinforcing, subjective and physiological effects of MDMA in humans; A comparison with d- amphetamine and mCPP. Drug Alcohol Depend 72:33-44.
164. Thomas JR, von Gunten CF (2003) Pain in terminally ill patients: guidelines for pharmacological management. CNS Drugs 17:621-631.
165. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacol (Berl) 167:85-96.
166. Unkefer RF (1990) Music Therapy in the Treatment of Adults with Mental Disorders: Theoretical Bases and Clinical Interventions. New York: Schirmer Books.
167. Van Dyke C, Stesin A, Jones R, Chuntharapai A, Seaman W (1986) Cocaine increases natural killer cell activity. J Clin Invest 77:1387-1390.
168. Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, De Visser S, Kuijerps M, Pennings EJM, de Bruin D, van de Wijngaart G, Van Gerven JM, Cohen A (2000) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacol (Berl) 153:196-202.
169. Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacol 19:241-251.
170. Vollenweider FX, Gamma A, Liechti M, Huber T (1999a) Is a single dose of MDMA harmless? Neuropsychopharmacol 21:598-600.
171. Vollenweider FX, Gucker P, Schonbachler R, Kamber E, Vollenweider- Scherpenhuyzen MFI, Schubiger G, Hell D (2000) Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans. Data presented at 2000 conference of the German Society for Psychiatry, Psychotherapy and Neuromedicine [Deutsche Gesellschaft fur psychiatrie, Psychotherapie und Nervenheilkunde].
172. Vollenweider FX, Jones RT, Baggott MJ (2001) Caveat emptor: editors beware. Neuropsychopharmacol 24:461-462.
173. Vollenweider FX, Remensberger S, Hell D, Geyer MA (1999b) Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacol (Berl) 143:365-372.
174. Wareing M, Fisk J, Murphy PN (2000) Working memory deficits in current and previous users of MDMA ("Ecstasy"). Br J Psychol 91:181-188.
175. Wareing M, Murphy PN, Fisk JE (2004) Visuospatial memory impairments in users of MDMA ("Ecstasy") Psychopharmacol (Berl) 173:391-397.
176. Wells N, Hepworth JT, Murphy BA, Wujcik D, Johnson R (2003) Improving cancer pain management through patient and family education. J Pain Symptom Management 25:344-356.
177. Widmer S (1998) Listening into the heart of things: The awakening of love: On MDMA and LSD: The undesired psychotherapy. Gerolfingen, Switzerland: Basic Editions.
178. Williams MT, Morford LL, Wood SL, Rock SL, McCrea AE, Fukumura M, Wallace TL, Broening HW, Moran MS, Vorhees CV (2003) Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res 968:89-101.
179. Zakzanis KK, Young DA (2001a) Memory impairment in abstinent MDMA ("ecstasy") users: A longitudinal investigation. Neurology 56:966-969.
180. Zakzanis KK, Young DA (2001b) Executive function in abstinent MDMA ("ecstasy") users. Med Sci Monitor 7:1292-1298.